- Trials with a EudraCT protocol (59)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
59 result(s) found for: Immune tolerance in pregnancy.
Displaying page 1 of 3.
EudraCT Number: 2018-000659-42 | Sponsor Protocol Number: TN-22 | Start Date*: 2019-03-12 |
Sponsor Name:TrialNet Coordinating Center | ||
Full Title: HYDROXYCHLOROQUINE FOR PREVENTION OF ABNORMAL GLUCOSE TOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1 DIABETES MELLITUS | ||
Medical condition: individuals at-risk for type 1 diabetes mellitus (T1D) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001232-27 | Sponsor Protocol Number: KLHExposure | Start Date*: 2012-06-04 |
Sponsor Name:Charité Universitaetsmedizin Berlin | ||
Full Title: Characterization of human peripheral and intestinal T-cell responses after mucosal antigen exposure: induction of tolerance vs. immunization by oral administration of KLH | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000608-39 | Sponsor Protocol Number: 21-ItolDC-028-01 | Start Date*: 2022-09-20 | |||||||||||
Sponsor Name:Idogen AB | |||||||||||||
Full Title: An open-label, multi-center, first in human, phase 1/2a trial to evaluate the safety and preliminary efficacy of autologous tolerogenic dendritic cells ex vivo loaded with recombinant Factor VIII (... | |||||||||||||
Medical condition: Treatment of patients with Hemophilia A who have developed inhibitory antibodies to clotting Factor VIII and have failed Immune Tolerance Induction | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007177-20 | Sponsor Protocol Number: Sirolimus_Liver_Tolerance | Start Date*: 2009-09-07 | |||||||||||
Sponsor Name:Hospital Clinic Barcelona | |||||||||||||
Full Title: EFECTO DEL SIROLIMUS SOBRE LOS BIOMARCADORES RELACIONADOS CON LA TOLERANCIA EN RECEPTORES DE TRASPLANTE HEPÁTICO ESTABLES | |||||||||||||
Medical condition: Stable liver transplant recipients identified as non-tolerant (i.e. requiring indefinite immunosuppressive therapy) on the basis of peripheral blood transcriptional biomarkers. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001915-78 | Sponsor Protocol Number: RBM/2004.20 | Start Date*: 2005-12-06 |
Sponsor Name:Institut Pasteur | ||
Full Title: A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of two doses 10 ^5 and 10^7 CFU of SC599 oral vaccine, a Live Attenuated Shigella dysenteriae 1 vaccine strain in ... | ||
Medical condition: Healthy Volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003456-20 | Sponsor Protocol Number: ITN084AD | Start Date*: 2020-02-17 | |||||||||||
Sponsor Name:Division of Allergy, Immunology, and Transplantation; National Institute of Allergy and Infectious Disease | |||||||||||||
Full Title: Grass Pollen Sublingual Tablet Immunotherapy plus Dupilumab for Induction of Tolerance in Adults with Moderate to Severe Seasonal Allergic Rhinitis. | |||||||||||||
Medical condition: Moderate to Severe Seasonal Allergic Rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000228-33 | Sponsor Protocol Number: CE/17-12-06 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU Saint-Pierre | |||||||||||||
Full Title: Prospective longitudinal study on immunogenicity, induction of cellular immune responses and safety of vaccination against HPV with the 9valent vaccine in HIV-positive women | |||||||||||||
Medical condition: Immune responses to administration of 9valent vaccine against HPV in HIV-positive women | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004557-14 | Sponsor Protocol Number: NA | Start Date*: 2015-02-09 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation | |||||||||||||
Medical condition: Immunosuppression withdrawal in liver transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000492-21 | Sponsor Protocol Number: 7678 | Start Date*: 2021-06-11 |
Sponsor Name:Les Hôpitaux Universitaires de Strasbourg | ||
Full Title: Multicenter randomized two arms study evaluating the efficacy of prophylactic Rituximab in adult EBV negative kidney transplant recipients on incidence of EBV primary infection and post-transplant ... | ||
Medical condition: Kidney transplantation Epstein Barr virus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004083-35 | Sponsor Protocol Number: 2017-53 | Start Date*: 2018-03-28 |
Sponsor Name:Assistance Publique Hôpitaux de Marseille | ||
Full Title: A double-blind, randomized, multicenter study evaluating 200 mg versus 600 mg of Mifepristone on pain in voluntary abortion by drug prior to 7 SA. DoMy Study | ||
Medical condition: patient of 18 years or more, wishing an abortion with medication before 7 weeks of amenorrhea | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006795-16 | Sponsor Protocol Number: 2021-3336 | Start Date*: 2022-11-18 |
Sponsor Name:GUSTAVE ROUSSY | ||
Full Title: Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study- PULSE | ||
Medical condition: Maintenance treatment in metastatic non-squamous lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004866-86 | Sponsor Protocol Number: P160944J | Start Date*: 2020-01-23 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Evaluation of the benefit of adjuvant treatment with hydroxychloroquine to usual medical care for uncomplicated term pregnancy in patients with primary obstetrical antiphospholipid syndrome: random... | |||||||||||||
Medical condition: Primary obstetrical antiphospholipid syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001857-14 | Sponsor Protocol Number: UC-0101/1709 | Start Date*: 2018-04-18 |
Sponsor Name:UNICANCER | ||
Full Title: A phase I/II basket trial evaluating a combination of Metronomic Oral Vinorelbine plus anti-PD-L1/anti-CTLA4 ImmunothErapy in patients with advanced solid tumours. | ||
Medical condition: Patients with Histologically confirmed locally advanced or metastatic solid tumours, resistant to conventional therapies, and candidate to experimental therapy by local clinical board, from the fol... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002735-23 | Sponsor Protocol Number: IPROTECT1 | Start Date*: 2013-12-04 | |||||||||||
Sponsor Name:InnaVirVax SA | |||||||||||||
Full Title: Assessment of the therapeutic properties of the VAC-3S immunoprotective vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. A European multicenter, r... | |||||||||||||
Medical condition: Chronically infected HIV-1 patients under viral control on Anti-Retroviral therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015113-44 | Sponsor Protocol Number: NEAT001 | Start Date*: 2010-05-19 | |||||||||||
Sponsor Name:ANSR | |||||||||||||
Full Title: Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ... | |||||||||||||
Medical condition: Infección por el virus de la inmunodeficiencia humana | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FR (Completed) SE (Completed) IE (Completed) DK (Completed) PT (Completed) AT (Completed) DE (Completed) GB (Completed) PL (Completed) IT (Completed) BE (Completed) NL (Completed) HU (Completed) GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001379-18 | Sponsor Protocol Number: QEL-001-CLN-01 | Start Date*: 2023-07-07 | |||||||||||
Sponsor Name:Quell Therapeutics Limited | |||||||||||||
Full Title: A single-arm, open-label, multi-centre, phase I/II study evaluating the safety and clinical activity of QEL-001, an autologous CAR T regulatory cell treatment targeting HLA-A2, in HLA-A2/ A28neg pa... | |||||||||||||
Medical condition: Prevention of liver transplant rejection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001587-30 | Sponsor Protocol Number: 012657 | Start Date*: 2019-07-26 | ||||||||||||||||
Sponsor Name:Queen Mary University London | ||||||||||||||||||
Full Title: AZD1656 in Transplantation with Diabetes tO PromoTe Immune TOleraNce | ||||||||||||||||||
Medical condition: renal transplant AND type 2 diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005346-58 | Sponsor Protocol Number: RIMINI | Start Date*: 2016-10-05 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI) | |||||||||||||
Medical condition: Rejection rate, graft loss or poor graft function defined as eGFR<40 ml/min in patients with kidney transplantation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003086-40 | Sponsor Protocol Number: PIX001 | Start Date*: 2008-04-08 |
Sponsor Name:Fondation Charcot Stichting | ||
Full Title: A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS) | ||
Medical condition: aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001317-20 | Sponsor Protocol Number: IMCY-T1D-003 | Start Date*: 2020-09-11 | |||||||||||
Sponsor Name:Imcyse SA | |||||||||||||
Full Title: A Phase Ib/IIa, randomized, double-blind placebo-controlled, multicenter adaptive design clinical trial to evaluate the immune signature of the treatment with the Imotope™ IMCY-0098 and its effect ... | |||||||||||||
Medical condition: Type 1 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) SI (Completed) LT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
